What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Money Flow Index

Score

-0.35

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 5 50.4 0.60% 1.50% 88.3% -25.5% 213.7%
SHORT 5 96.0 0.20% 0.25% 5.5% -10.8% -37.6%

Summary

Technical Analysis

Opthea (OPT.AX)


Indicator:

MONEY FLOW INDEX


Last Signal:

NEUTRAL


Trading: NO POSITION
Signal Strength: MEDIUM


Money Flow Index (MFI) is a volume-based indicator it could be used in technical analysis to measure the strength of money flow in and out of a security index and market. The principle of MFI calculation is a comparison of positive money flow to negative money flow. MFI is also known as volume-weighted RSI. MFI starts with the typical price for each period. The same as RSI the MFI scale is between 0 and 100.

Calculation: Money Flow Index (MFI):
1) Typical Price = (High + Low + Close)/3;
2) Raw Money Flow = Typical Price x Volume;
3) Money Flow Ratio = (14-period Positive Money Flow)/(14-period Negative Money Flow);
4) Money Flow Index = 100 - 100/(1 + Money Flow Ratio)


PROFILE: Opthea (OPT.AX)


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:

Money Flow Index

Download
Company Close Change(%) Volume Value Signal
REX Regional Express 0.54 33.8 285,693 32.5 NEUTRAL
AJX Alexium International 0.04 17.6 638,300 34.19 NEUTRAL
MNS Milnes Holdings 0.07 16.4 1,475,601 42.12 NEUTRAL
ATL ASX 20 0.1 16.3 289,754 31.96 NEUTRAL
BFC Beston Global Food 0.08 14.3 399,394 62.7 NEUTRAL
VRL Village Roadshow 1.14 14 354,335 30.04 NEUTRAL
SXY Senex Energy 0.17 13.8 12,737,087 62.46 NEUTRAL
KMD Kathmandu 0.96 13 1,085,149 29.07 NEUTRAL
BEE Broo 0.01 12.5 126,198 25.83 NEUTRAL
AGI Ainsworth Game Technology 0.41 12.3 313,697 32.45 NEUTRAL